National University of Ireland - Doctor of Medicine Baylor Clinic & Hospital - Fellowship - Pharmacology Baylor Clinic & Hospital - Residency - Internal Medicine University College Hospital Galway - NUI - Residency - Internal Medicine University College Hospital Galway - NUI - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)
Josephine M. Egan - Baltimore MD, US Máire E. Doyle - Gainesville FL, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12N 5/00
US Classification:
435325
Abstract:
Disclosed are methods for identifying and isolating a precursor cell. Also, disclosed are methods of increasing insulin synthesis from a pancreatic B-cell. Further, disclosed are methods of improving pancreatic B-cell function. Still further, disclosed are methods of preventing or delaying the onset of a metabolic disease, methods of treating or preventing a metabolic disease in a subject, and to compositions for treating or preventing a metabolic disease in a subject in need of such treatment or prevention.
Josephine Egan - Baltimore MD, US Stephen Gravine - Rutherford NJ, US Robert Margolskee - Upper Montclair NJ, US Richard McGregor - Rutherford NJ, US Lenore Snyder - New York NY, US Michael Theodorakis - Baltimore MD, US
International Classification:
C12Q001/00
US Classification:
435004000
Abstract:
Disclosed are materials and methods relevant to taste transduction. Also disclosed are human gastrointestinal cells that comprise or are capable expressing endogenous taste signaling proteins. Also disclosed are human gastrointestinal cells that comprise or are capable of expressing endogenous taste signaling proteins as well as hormones, neurotransmitters or soluble mediators of the gastrointestinal tract that are involved in or affect metabolism, digestion and appetite. Also disclosed are the uses of these human cells or their membranes to study how compounds affect taste transduction and/or metabolism, digestion and appetite, including effects on satiety, emesis and diabetes.
Differentiation Of Non-Insulin Producing Cells Into Insulin Producing Cells By Glp-1 Or Exendin-4 And Uses Thereof
Josephine Egan - Baltimore MD, US Riccardo Perfetti - Washington DC, US Antonino Passaniti - White Hall MD, US Nigel Greig - Silver Spring MD, US Harold Holloway - Middle River MD, US Joel Habener - Newton Centre MA, US Doris Stoffers - Moorestown NJ, US
International Classification:
A61K 35/39 C12N 5/08
US Classification:
424093700, 435366000, 435325000
Abstract:
The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragments thereof. The present invention also relates to methods of differentiating non-insulin producing cells into insulin producing cells and of enriching a population of cells for insulin-producing cells. The present invention also relates to methods of treating diabetes.
Differentiation Of Non-Insulin Producing Cells Into Insulin Producing Cells By Glp-1 Or Exendin-4 And Uses Thereof
Josephine Egan - Baltimore MD, US Riccardo Perfetti - Washington DC, US Antonino Passaniti - White Hall MD, US Nigel Greig - Silver Spring MD, US Harold Holloway - Middle River MD, US Joel Habener - Newton Centre MA, US Doris Stoffers - Moorestown NJ, US
Assignee:
The United States of America as represented by the Department of Health and Human Services, NIH - Washington DC
International Classification:
C12N 5/00
US Classification:
435325, 530308
Abstract:
The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragmets thereof. The present invention also relates to methods of differentiating non-insulin producing cells into insulin producing cells and of enriching a population of cells for insulin-producing cells. The present invention also relates to methods of treating diabetes.
Glp-1, Exendin-4, Peptide Analogs And Uses Thereof
- Rockville MD, US Josephine M. Egan - Baltimore MD, US Maire Doyle - Baltimore MD, US Harold W. Holloway - Middle River MD, US Tracy Perry - Baltimore MD, US
International Classification:
C07K 14/575
US Classification:
514 67, 514 117, 514 97
Abstract:
The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.